Sarcode Bioscience Inc.

Abbott Laboratories Corporation

Amgen Inc.

University of Pittsburgh

Newgen Therapeutics, Inc.

Sarcode Corporation

Jiangsu Kanion Pharmaceutical Co., Ltd.

Cocrystal, Discovery, Inc.

Sunesis Pharmaceuticals, Inc.

Cocrystal Pharma, Inc.

Rakovina Therapeutics Inc.

Wang Shen

Kenneth Jay Barr

Min Zhong

Johan D Oslob

Saul H Rosenberg

David John Augeri

Xiaoling Zheng

Julio Cesar Medina

Stephen J O'Connor

Stephen A Fakhoury

Jonathan B Houze

Gerard M Sullivan

Jiwen Liu

Yingcai Wang

Michael D Wendt

Hong Ding

William J McClellan

Zice Fu

Paul John Dransfield

Daniel A Dickman

Sheela A Thomas

Marc Vimolratana

Aimin Zhang

Said M Sebti

Andrew D Hamilton

Ming Yu

Jack Maung

Todd J Kohn

XianYun Jiao

SuJen Lai

David S Garvey

Thorsten K Oost

Xilu Wang

Le Wang

Xiaohui Du

Aaron R Kunzer

Milan Bruncko

Todd Warren Rockway

Liusheng Zhu

Zhihua Ma

Stephen W Fesik

Anthony K Fung

Irina C Jacobson

Vatee Pattaropong

Sean P Brown

William R Baker

Andrew M Petros

Wei Xiao

An-Rong Li

Zhongyu Wang

Jurgen Dinges

Kenneth J Henry

Jinqian Liu

Philip J Hajduk

James T Wasicak

Rajnandan N Prasad

Steven A Baumeister

Andrew Stewart Tasker

Steven Elmore

Haiying He

Bryan K Sorensen

Rajiv Sharma

Hilary Plake Beck

David M Stout

Zhenzhong Wang

Herman H Stein

Douglas M Kalvin

Shuhui Chen

Michael J Schmitt

Rolf E Swenson

Indrani W Gunawardana

Peng Li

David A Janowick

Bailing Yang

Yong-Jae Kim

David G Nettesheim

Lissa T J Nelson

Gang Liu

Thomas Gadek

Matthew Irvine Brown

Jian Luo

John P Burnier

Michael G Johnson

Leping Li

Jian Li

David L Arendsen

Sarah Lively

Gayathri Swaminath

Ning Li

Jie Zhang

Mike Elias Lizarzaburu

YuMei Xiong

Xian Yun Jiao

Yongli Su

Sam S K Lee

Zongbin Li

Sam S Lee

Xuemei Wang

Margrit Schwarz

Jeffrey D Reagan

The invention provides alkyne substituted quinazoline compounds, such as compounds of the formula (I), which are irreversible ErbB kinase inhibitors. The compounds are useful in the treatment of diseases and disorders where ErbB kinase activity is implicated such as a hyperproliferative disorder (e.g., cancer).

Alkyne substituted quinazoline compound and methods of use

The invention provides for compositions comprising phosphorous containing tricyclic compounds, including phthalazin-1(2H)-one derivatives. The compounds are potent inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), particularly PARP-1 and potentially PARP-2. The also show good cellular activity in inhibiting poly(ADP-ribose) oligomer formation. The compounds may be useful as mono-therapy or in combination with other therapeutic agents in the treatment conditions where PARP is implicated, such as cancer, inflammatory diseases and ischemic conditions. Thus, also provided are methods for the treatment of a condition where PARP is implicated comprising administering to an effective amount of a compound of the invention to an individual in need thereof.

Tricyclic inhibitors of poly(ADP-ribose)polymerase

The present invention provides, among other things, compounds represented by the general Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, R, and Rare as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection. 

Inhibitors of hepatitis C virus polymerase

The present invention discloses a salt form, crystal form and intermediate of the compound 1, and preparation method thereof. 

Salt form and crystal form of 1,2,5-thiadiazolidin-1,1-dioxide, preparation method thereof and intermediate

The present invention provides compounds having formula (I): 

Modulators of cellular adhesion

Disclosed is a novel anti-enterovirus 71 (EV71) 1,2,5-thiadiazolidine-1,1-dioxide derivative or a pharmaceutically acceptable salt thereof, and specifically, a compound represented by formula (II) or a pharmaceutically acceptable salt thereof. 

Anti-enterovirus 71 thiadiazolidine derivative

The invention provides quinazoline-7-ether derivatives, particularly 4-anilinyl-6-butenamido-quinazoline-7-ether derivatives that are inhibitors of the receptor protein tyrosine kinases (RTK). The compounds are useful in the treatment of diseases and disorders where RTK activity is implicated such as a hyperproliferative diseases (e.g., cancer). Also provided are methods of preparation of the quinazoline derivatives and methods of use as therapeutic agents alone or in a drug combination.

Quinazoline-7-ether compounds and methods of use

The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.

Compositions and methods for treatment

Disclosed are novel quinazoline derivatives containing phosphorus substitutions and methods for the treatment of hyperproliferative diseases (e.g. cancer) using the compounds. These compounds are type I receptor protein kinase inhibitors useful in treating disorders related to abnormal protein kinase activities such as cancer and inflammation in mammals. Also disclosed are pharmaceutical compositions containing the compounds, methods for the preparation of the compounds and their pharmaceutically acceptable salts.

Phosphorus containing quinazoline compounds and methods of use

Growing community of inventors

San Mateo, CA, United States of America

Wang Shen